Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

June 30, 2028

Conditions

Dilated Cardiomyopathy (DCM)Heart Failure

Interventions

BIOLOGICAL

FAP immunosuppressive CAR-DC

Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER